The estimated Net Worth of Torsten Hoof is at least $1.09 Million dollars as of 24 September 2020. Mr. Hoof owns over 4,401 units of Exact Sciences stock worth over $411,522 and over the last 5 years he sold EXAS stock worth over $676,144. In addition, he makes $0 as General Manager - International at Exact Sciences.
Sign up
Mr. Hoof EXAS stock SEC Form 4 insiders trading
Torsten has made over 4 trades of the Exact Sciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 4,401 units of EXAS stock worth $182,774 on 24 September 2020.
The largest trade he's ever made was selling 7,964 units of Exact Sciences stock on 19 August 2020 worth over $676,144. On average, Torsten trades about 2,835 units every 37 days since 2019. As of 24 September 2020 he still owns at least 6,418 units of Exact Sciences stock.
You can see the complete history of Mr. Hoof stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Torsten Hoof biography
Torsten Hoof serves as General Manager - International of the Company. Mr. Hoof joined Genomic Health in September 2017 as Senior Vice President, International. Mr. Hoof previously served from May 2015 to March 2017 as the Vice President and Head of Oncology EMEA at Baxalta, where he built the company's oncology presence in Europe. From February 2013 to October 2014, Mr. Hoof was also the European General Manager for Endocyte, where he established its European organization designed to bring an innovative, precision medicine solution to patients with ovarian cancer. During his 10 years at Bristol-Myers Squibb, he led the global haemato-oncology franchise and was EMEA General Manager and Vice President for HIV and Primary Care. In his career with Roche, Torsten led the Tamiflu launch as a Global Business Leader and established Roche's German leadership position in Virology. Torsten also served as an Independent Director at HRA Pharma until its acquisition by Goldman Sachs and Astorg in February 2016. Mr. Hoof earned PhD and master's degrees from the University of Hannover, Germany and is an alumnus of the Boehringer Ingelheim Fonds, Germany.
How old is Torsten Hoof?
Torsten Hoof is 60, he's been the General Manager - International of Exact Sciences since 2019. There are 8 older and 17 younger executives at Exact Sciences. The oldest executive at Exact Sciences Corp. is James Doyle, 74, who is the Independent Director.
What's Torsten Hoof's mailing address?
Torsten's mailing address filed with the SEC is C/O EXACT SCIENCES CORP., 5505 ENDEAVOR LANE, MADISON, WI, 53719.
Insiders trading at Exact Sciences
Over the last 21 years, insiders at Exact Sciences have traded over $118,141,352 worth of Exact Sciences stock and bought 191,930 units worth $1,451,887 . The most active insiders traders include Kevin T Conroy, Edwin M Jr Kania und Maneesh Arora. On average, Exact Sciences executives and independent directors trade stock every 12 days with the average trade being worth of $1,667,056. The most recent stock trade was executed by Brian Baranick on 5 August 2024, trading 2,712 units of EXAS stock currently worth $173,893.
What does Exact Sciences do?
exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences' noninvasive colon cancer screening test, visit cologuardtest.com
What does Exact Sciences's logo look like?
Complete history of Mr. Hoof stock trades at Exact Sciences
Exact Sciences executives and stock owners
Exact Sciences executives and other stock owners filed with the SEC include:
-
Kevin Conroy,
Chairman of the Board, President, Chief Executive Officer -
Mark Stenhouse,
General Manager - Screening -
Jeffrey Elliott,
Chief Financial Officer -
D. Scott Coward,
Senior Vice President, Chief Administrative Officer, General Counsel, Secretary -
Jake Orville,
General Manager - Pipeline -
Ana Hooker,
Senior Vice President, Operations -
Graham Lidgard,
Senior Vice President, Chief Scientific Officer -
Kevin T. Conroy,
Chairman, Pres & CEO -
G. Bradley Cole,
Gen. Mang. of Precision Oncology -
Mark Stenhouse,
Advisor -
Graham P. Lidgard,
Emeritus Chief Science Officer -
Jeffrey T. Elliott CFA,
Exec. VP, CFO & COO -
D. Scott Coward,
Chief Admin. Officer, Exec. VP, Gen. Counsel & Sec. -
Kathleen Sebelius,
Independent Director -
Andrew Slavitt,
Director -
Pierre Jacquet,
Independent Director -
Jake Orville,
Gen. Mang. of Pipeline -
Ana Hooker,
Sr. VP of Operations -
James Doyle,
Independent Director -
Michael Wyzga,
Independent Director -
Daniel Levangie,
Independent Director -
Katherine Zanotti,
Independent Director -
Thomas Carey,
Independent Director -
Shacey Petrovic,
Director -
Gisela Paulsen,
General Manager - Precision Oncology -
Torsten Hoof,
General Manager - International -
Freda Lewis-Hall,
Independent Director -
Scott Johnson,
Senior Vice President, Research and Development -
Vic Parker,
Head of Sales -
Tim Caprez,
Chief Compliance Counsel & VP -
Megan Jones,
Associate Mang. of Investor Relations -
Dr. Scott C. Johnson Ph.D.,
Chief Science Officer and Sr. VP of R&D -
Gary Frings,
Chief Information Officer -
Lionel Sterling,
Director -
John A. Fallon,
Director -
David Thompson,
Director -
G Bradley Cole,
General Manager - Diagnostics -
Paul J Clancy,
-
Michael J Barber,
-
Eli Casdin,
Director -
Anthony P Shuber,
Executive Vice President -
John A Jr Mccarthy,
Chief Financial Officer -
Don M Hardison,
President, CEO and Director -
Barry M Berger,
SVP, Chief Medical Officer -
William J. Megan,
SVP, Finance & PFO -
John K Bakewell,
Chief Financial Officer -
Jeffrey R Luber,
General Counsel -
Edwin M Jr Kania,
Director -
Charles R Jr Carelli,
Prin. Acct. Off. & Corp. Ctlr. -
Patrick J Zenner,
Director -
Stanley N Lapidus,
Director -
John M Krayacich,
SVP, Sales and Marketing -
Richard W Barker,
Director -
Laura S Stoltenberg,
Chief Commercial Officer -
Cornelius Iii Mcgillicudy,
Director -
Harry W Wilcox,
Senior Vice President and CFO -
Lance Willsey,
Director -
Michael E Singer,
Director -
Maneesh Arora,
Vice President -
James P Connelly,
Director -
Sally Crawford,
Director -
Sarah Condella,
EVP, Human Resources -
Timothy J Scannell,
Director -
James Herriott,
SVP, General Counsel & Sec -
Everett Cunningham,
Chief Commercial Officer -
Jacob A Orville,
EVP, GM, Screening -
Brian Baranick,
EVP, GM, Precision Oncology